$1.9 Billion in mRNA Vaccine Revenue

Moderna, Inc. today announced financial results and provided business updates for the first quarter of 2023.

"We had a strong first quarter, with $1.9 billion in revenue, clearly indicating that we are on our way to deliver on the $5 billion of signed Advance Purchase Agreements for 2023," said Stéphane Bancel, Chief Executive Officer of Moderna, in a press release.

"In addition, we are encouraged by the progress of new COVID-19 vaccine contracts in the U.S. for this fall with pharmacy chains, hospital networks, and multiple U.S. government agencies."

"Similar discussions are ongoing with Japan, the EU, and other key markets such as Australia, which recently ordered additional COVID-19 vaccines."

"..... we are fully preparing for potential commercial launches of two products in 2024, our RSV and flu vaccines."

Moderna's respiratory pipeline includes Phase 3 trials against RSV, influenza, and a next-generation COVID-19 candidate.

The mRNA pipeline includes four additional influenza vaccines with expanded antigens, vaccines against other respiratory pathogens (e.g., hMPV), and six combination vaccine programs.

Moderna's unedited press release is posted at this link.